Preventive Cardiology - The Horizon Study

The Horizon Study is a randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with known cardiovascular disease.  This study is being conducted by Dr. Paul Thompson and Preventive Cardiology.

Eligibility Criteria:

  • Age 18-80 with an Lp(a) >70 mg/dl
  • Currently on optimal LDL-C lowering therapy according to local guidelies

Please contact Karen Knight, Coordinator at 860-972-1696 or email at for additional information.